Fellowship · Los Angeles, CA
Sponsored by Children's Hospital Los Angeles
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature · 2021 · 552 citations · Sia Daneshmand
Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
European urology · 2026 · 37 citations · Sia Daneshmand
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
The Lancet. Oncology · 2023 · 211 citations · Sia Daneshmand
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology · 2021 · 369 citations · Sia Daneshmand
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
European urology · 2024 · 134 citations · Sia Daneshmand
Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023.
The Journal of urology · 2024 · 78 citations · Sia Daneshmand
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 42 citations · Sia Daneshmand
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Nature medicine · 2023 · 138 citations · Sia Daneshmand